Anfield Energy priced a $6M public offering of 1.49M shares at $4 each. Proceeds fund uranium projects in Utah. Closing expected July 31. Dilution risk for shareholders.
Alpha Score of 49 reflects weak overall profile with strong momentum, poor value, moderate quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.
Anfield Energy priced a $6 million underwritten public offering of 1.49 million common shares at $4 each. The uranium developer is selling the shares through a syndicate led by Northland Capital Markets and Roth Capital Partners. Closing is expected on or about July 31, subject to TSX Venture Exchange approval.
The underwriters have a 30-day option to buy up to 223,695 additional shares at the same price. If exercised in full, the total gross proceeds would reach $6.9 million.
Anfield said it will use the net proceeds to fund capital commitments at the Paradox Complex, the Velvet-Wood Project, the Slick Rock Complex, and the Shootaring Canyon Mill in Utah. The remainder goes to working capital and general corporate purposes.
The company’s flagship asset is the Shootaring Canyon Mill, one of three licensed, permitted conventional uranium mills in the United States. Its portfolio also includes the advanced Velvet-Wood project and other conventional uranium-vanadium assets across Utah, Colorado, Arizona, and New Mexico.
Anfield positions itself as a domestic supplier to the U.S. nuclear fuel market. The country consumes nearly 50 million pounds of uranium each year but produces only a small fraction of that volume internally.
The offering dilutes existing shareholders by roughly 8.6% based on the current share count before the over-allotment. Anfield’s stock trades on the TSX Venture Exchange and the Nasdaq under the ticker AEC. For more on the broader commodities analysis, see AlphaScala’s coverage.
Prepared with AlphaScala editorial tooling from the source reporting linked above. Indexable analysis may include a cited Alpha Score value. Publishing checks screen each story before release. Educational coverage, not personalized advice.